BioArctic AB (publ) Asset Resilience Ratio
BioArctic AB (publ) asset resilience ratio. BioArctic AB (publ) (BIOA-B) has an Asset Resilience Ratio of 32.23% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read BioArctic AB (publ) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of BioArctic AB (publ) (2017–2025)
Asset resilience ratio of BioArctic AB (publ) from 2017 to 2025. This chart shows how BioArctic AB (publ)'s Asset Resilience Ratio has changed over time. See BioArctic AB (publ) (BIOA-B) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down BioArctic AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see BioArctic AB (publ) (BIOA-B) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr908.65 Million | 32.23% |
| Total Liquid Assets | Skr908.65 Million | 32.23% |
Asset Resilience Insights
- Very High Liquidity: BioArctic AB (publ) maintains exceptional liquid asset reserves at 32.23% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
BioArctic AB (publ) Industry Peers by Asset Resilience Ratio
Compare BioArctic AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.57% |
|
Eupraxia Pharmaceuticals Inc
TO:EPRX |
Biotechnology | 25.13% |
|
Cabio Biotech Wuhan Co Ltd
SHG:688089 |
Biotechnology | 3.60% |
BioArctic AB (publ) Asset Resilience Ratio by Year (2017–2025)
BioArctic AB (publ) asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for BioArctic AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 85.06% | Skr2.19 Billion ≈ $235.73 Million |
Skr2.58 Billion ≈ $277.14 Million |
+14.99pp |
| 2024-12-31 | 70.07% | Skr778.92 Million ≈ $83.82 Million |
Skr1.11 Billion ≈ $119.63 Million |
+27.91pp |
| 2023-12-31 | 42.16% | Skr500.00 Million ≈ $53.81 Million |
Skr1.19 Billion ≈ $127.64 Million |
-52.35pp |
| 2021-12-31 | 94.51% | Skr848.40 Million ≈ $91.30 Million |
Skr897.73 Million ≈ $96.61 Million |
-0.70pp |
| 2020-12-31 | 95.20% | Skr999.94 Million ≈ $107.61 Million |
Skr1.05 Billion ≈ $113.03 Million |
+1.17pp |
| 2019-12-31 | 94.04% | Skr1.11 Billion ≈ $119.75 Million |
Skr1.18 Billion ≈ $127.35 Million |
+28.19pp |
| 2018-12-31 | 65.85% | Skr917.31 Million ≈ $98.72 Million |
Skr1.39 Billion ≈ $149.91 Million |
-31.51pp |
| 2017-12-31 | 97.36% | Skr1.11 Billion ≈ $119.49 Million |
Skr1.14 Billion ≈ $122.73 Million |
-- |
About BioArctic AB (publ)
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and ALS. In addition, it offers lecanemab for in… Read more